Ultimovacs

Ultimovacs is a pharmaceutical company developing novel immunotherapies for cancer. The lead product candidate is UV1, a peptide-based vaccine that induces specific T-cell responses against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine to be used in combination with other immuno-oncology drugs whose mechanisms of action require sustained T-cell responses. Ultimovacs is conducting an extensive clinical development program in Europe and the United States, with ongoing clinical trials.